AC0058

AC0058 is a small molecule drug that acts as a potent, selective, and irreversible inhibitor of Bruton's tyrosine kinase (BTK). By inhibiting BTK phosphorylation and downstream signaling pathways, it disrupts the activation of B cells and inflammatory cytokine production in monocytes. This mechanism makes it a promising targeted therapy for autoimmune diseases characterized by aberrant B cell activity—most notably systemic lupus erythematosus (SLE). Preclinical studies have shown its potential to control excessive T and B cell activation. Clinical development has included Phase I trials in healthy volunteers demonstrating safety and high BTK occupancy (>90%), with ongoing Phase Ib studies in SLE patients. The drug is also being explored for other autoimmune indications such as multiple sclerosis[1][2][5][7][8].